While randomized controlled trials (RCTs) have traditionally been considered the gold standard for drug development, it is widely recognized that RCTs are expensive, lengthy, and burdensome on patients. According to some estimates, it takes more than a billion dollars in funding and a decade of work to bring one new medication to market. Despite exciting advances in genomics, patient-centric awareness, decentralized clinical trials, and the application of artificial intelligence (AI), there is a lack of compelling evidence to date that these trends have had a significant impact on the time and cost of the typical oncology clinical trial.
Read More